Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 15/20 | 0.65 |
| ▸ | ITGB7 | P26010 | 15/20 | 0.65 |
| ▸ | ITGB1 | P05556 | 13/20 | 0.65 |
| ▸ | CNR2 | P34972 | 4/20 | 0.46 |
| ▸ | CNR1 | P21554 | 3/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16489169 | 1.00 | ITGA4 (0.65) | ITGA4ITGB7ITGB1CNR2CNR1 | |
| SCHEMBL10329623 | 0.93 | ITGA4 (0.63) | ITGA4ITGB7ITGB1PGR | |
| SCHEMBL29374360 | 0.91 | ITGA4 (0.77) | ITGA4ITGB7ITGB1 | |
| SCHEMBL10329613 | 0.91 | ITGA4 (0.77) | ITGA4ITGB7ITGB1 | |
| SCHEMBL6015064 | 0.91 | ITGA4 (0.69) | ITGA4ITGB7ITGB1 | |
| SCHEMBL13819338 | 0.91 | ITGA4 (0.69) | ITGA4ITGB7ITGB1CNR2CNR1 | |
| SCHEMBL13376836 | 0.90 | ITGA4 (0.66) | ITGA4ITGB7ITGB1CNR2CNR1 | |
| SCHEMBL10330085 | 0.89 | ITGA4 (0.65) | ITGA4ITGB7ITGB1PGR | |
| SCHEMBL13376835 | 0.89 | ITGA4 (0.65) | ITGA4ITGB7ITGB1PGR | |
| SCHEMBL10329620 | 0.89 | ITGA4 (0.60) | ITGA4ITGB7ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230033021-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN INTEGRIN INHIBITOR | GLAS USA LLC | 2023-02-02 | — | — | US | disclosed |
| US-10562898-B2 | Substituted benzenesulfonamides as inhibitors of alpha-4 beta-7 integrin activity | EA PHARMA CO., LTD. (JP) | 2020-02-18 | — | — | US | disclosed |
| US-20190040059-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | EA PHARMA CO., LTD. (JP) | 2019-02-07 | — | — | US | disclosed |
| WO-2017135471-A1 | INTEGRIN α4β7 INHIBITOR | ＥＡファーマ株式会社 | 2017-08-10 | — | — | WO | disclosed |
| WO-2017135472-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | ＥＡファーマ株式会社 | 2017-08-10 | — | — | WO | disclosed |
| US-20160264566-A1 | ANTI-ALPHAVBETA1 INTEGRIN INHIBITORS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-15 | — | — | US | disclosed |
| US-20160264566-A1 | ANTI-ALPHAVBETA1 INTEGRIN INHIBITORS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-15 | — | — | US | disclosed |
| US-8426588-B2 | Phenylalanine derivatives | AJINOMOTO CO, INC. (JP) | 2013-04-23 | — | — | US | disclosed |
| US-8426588-B2 | Phenylalanine derivatives | AJINOMOTO CO, INC. (JP) | 2013-04-23 | — | — | US | disclosed |
| US-20120253041-A1 | NEW PHENYLALANINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2012-10-04 | — | — | US | disclosed |
| US-20120253041-A1 | NEW PHENYLALANINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2012-10-04 | — | — | US | disclosed |
| US-8222405-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2012-07-17 | — | — | US | disclosed |
| US-8222405-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20110065918-A1 | NEW PHENYLALANINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2011-03-17 | — | — | US | disclosed |
| US-20110065918-A1 | NEW PHENYLALANINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2011-03-17 | — | — | US | disclosed |
| US-7872125-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-7872125-B2 | Phenylalanine derivatives | AJINOMOTO CO., INC. (JP) | 2011-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562898-B2 | Substituted benzenesulfonamides as inhibitors of alpha-4 beta-7 integrin activity | ITGB4, ITGB7, ITGA4 | ITGA4 3/4885ITGB7 2/4885ITGB1 4/4885 |
| US-20190040059-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | ITGB4, ITGB5, ITGA4 | ITGA4 3/4885ITGB7 14/4885ITGB1 8/4885 |
| US-20230033021-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN INTEGRIN INHIBITOR | ITGAL, ITGB2, ITGB1 | ITGA4 17/4885ITGB7 20/4885ITGB1 3/4885 |
| US-20160264566-A1 | ANTI-ALPHAVBETA1 INTEGRIN INHIBITORS AND METHODS OF USE | ITGB1, ITGA1, ITGAV | ITGA4 10/4885ITGB7 9/4885ITGB1 1/4885 |
| US-20110065918-A1 | NEW PHENYLALANINE DERIVATIVES | ITGB4, ITGA4, ITGAV | ITGA4 2/4885ITGB7 20/4885ITGB1 13/4885 |
| US-20120253041-A1 | NEW PHENYLALANINE DERIVATIVES | ITGB4, ITGA4, ITGAV | ITGA4 2/4885ITGB7 20/4885ITGB1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.